Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2009-03-16
2010-11-23
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S025000, C514S026000
Reexamination Certificate
active
07838500
ABSTRACT:
The invention relates to a crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.
REFERENCES:
patent: 6815428 (2004-11-01), Ohsumi et al.
patent: 6908905 (2005-06-01), Ohsumi et al.
patent: 7015201 (2006-03-01), Ohsumi et al.
patent: 7247616 (2007-07-01), Ohsumi et al.
patent: 7256209 (2007-08-01), Ohsumi et al.
patent: 7375090 (2008-05-01), Himmelsbach et al.
patent: 7439232 (2008-10-01), Kakinuma et al.
patent: 2003/0054453 (2003-03-01), Curtis et al.
patent: 2005/0143424 (2005-06-01), Maezono et al.
patent: 2005/0233982 (2005-10-01), Himmelsbach et al.
patent: 2007/0072813 (2007-03-01), Himmelsbach et al.
patent: 2007/0099979 (2007-05-01), Ohsumi et al.
patent: 2007/0270479 (2007-11-01), Ohsumi et al.
patent: 2007/0281940 (2007-12-01), Dugi
patent: 2008/0020987 (2008-01-01), Pfrengle
patent: 2003262262 (2004-03-01), None
patent: 2 494 179 (2004-02-01), None
patent: 2 496 329 (2004-03-01), None
patent: 2 500 873 (2004-04-01), None
patent: 2 507 665 (2004-06-01), None
patent: 2 539 032 (2005-03-01), None
patent: 1 213 296 (2002-06-01), None
patent: 1 338 603 (2003-08-01), None
patent: 1 364 888 (2003-10-01), None
patent: 1 389 621 (2004-02-01), None
patent: 1 400 529 (2004-03-01), None
patent: 1 500 403 (2005-01-01), None
patent: 1 550 668 (2005-07-01), None
patent: 1 609 799 (2005-12-01), None
patent: 1 637 539 (2006-03-01), None
patent: 2003/12686 (2003-01-01), None
patent: 03/020737 (2003-03-01), None
patent: 2004/014932 (2004-02-01), None
patent: 2004/018491 (2004-03-01), None
patent: 2004/019958 (2004-03-01), None
patent: 2004/031203 (2004-04-01), None
patent: 2004/050122 (2004-06-01), None
patent: 2004/089966 (2004-10-01), None
patent: 2004/113359 (2004-12-01), None
patent: 2005/021566 (2005-03-01), None
patent: 2007/010015 (2007-01-01), None
patent: 2007/014895 (2007-02-01), None
patent: 2007/128761 (2007-11-01), None
D. Giron; Thermal Analysis and Calorimetric Methods in the Characterisation of Polymorphs and Solvates; Thermochimica Acta (1995) vol. 248 pp. 1-59.
Bruce C. Hamper et al; Cyclocondensation of Alkylhydrazines and Beta-Substituted Acetylenic Esters: Synthesis of 3-Hydroxypyrazoles; Journal Organic Chemistry (1992) vol. 57 pp. 5680-5686.
Pyrazolinone Herbicides; Chemical Abstract Service (1981) p. 151890.
C. A. Rojahn; 1-Alkyl-3-Chloropyrazoles and 1-Alkyl-3-Pyrazolones; Chemical Abstract Service (1923) p. 6867.
V. I. Saloutin et al; Study of the Reaction of Fluoroalkyl Beta-Ketoesters with Methylhydrazine; Bulletin of the Academy of Sciences of the USSR (1988) vol. 37 No. 12 pp. 318-321.
Diane Zimmermann et al; Unambiguous Synthesis of 1-Methyl-3-Hydroxypyrazoles; Tetrahedron (1998) vol. 54 No. 32 pp. 9393-9400; Elsevier Science Publishers.
International Search Report for PCT/EP2006/064435 mailed Nov. 22, 2006.
International Search Report for PCT/EP2006/064715 mailed Feb. 21, 2007.
International Search Report for PCT/EP2007/050209 mailed Apr. 13, 2007.
Ernest M. Wright et al; The Sodium/Glucose Cotransport Family SLC5; European Journal Renal Physiology (2004) vol. 447 pp. 510-518.
Guofeng You et al; Molecular Characteristics of Na+ -Coupled Glucose Transporters in Adult and Embryonic Rat Kidney; The Journal of Biological Chemistry (1995) vol. 270 No. 49 pp. 29365-29371.
Ana M. Pajor et al; Cloning and Functional Expression of a Mammalian Na+/Nucleoside Cotransporter; The Journal of Biological Chemistry (1992) vol. 267 No. 6 pp. 3557-3560.
Lubing Zhou et al; Human Cardiomyocytes Express High Level of Na+/Glucose Cotransporter 1 (SGLT1); Journal of Cellular Biochemistry (2003) vol. 90 pp. 339-346.
Ana Diez-Sampedro et al; A Glucose Sensor Hiding in a Family of Transporters; The National Academey of Sciences of the USA (2003) vol. 100 No. 20 pp. 11753-11758.
Niloofar M.Tabatabai et al; Mouse Kidney Express mRNA of Four Highly Related Sodium-Glucose Cotransporters: Regulation by Cadmium; Kidney International (2003) vol. 64 pp. 1320-1330.
Walter L. Gouvea et al; Phlorizin-Induced Glycosuria Does Not Prevent Gentamicin Nephrotoxicity in Rats; Kidney International (1989) vol. 35 pp. 1041-1048.
Ernerst M. Wright; Renal Na+ -Glucose Cotransporters; American Journal Physiological Renal Physiological (2001) vol. 280 pp. F10-F18.
James I. Cleeman et al; Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III); Journal of the American Medical Association (2001) vol. 285 No. 19 pp. 2486-2497.
International Search Report for PCT/EP2006/064715 mailed on Feb. 21, 2007.
European Search Report for EP 05 01 6390 mailed on May 30, 2006.
Luciano Rossetti et al; Correction of Hyperglycemia with Phlorizin Normalizes Tissue Sensitivity to Insulin in Diabetic Rats; Journal Clinical Investigation (1987) vol. 79 pp. 1510-1515.
U.S. Appl. No. 11/490,426, filed Jul. 20, 2006.
U.S. Appl. No. 11/744,703, filed May 4, 2007.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, “Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ill)”, JAMA, 2001, vol. 285, No. 13, p. 2486.
M. Stumvoll, et al., “The OGTT as test for beta cell function?”, European Journal of Clinical Investigation, 2001, vol. 31, p. 380-381.
American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases, The Prevention or Delay of Type 2 Diabetes, Diabetes Care, 2002, vol. 25, No. 4, p. 742.
A. Katsuki, et al., “Homeostasis Model Assessment is a Reliable Indicator of Insulin Resistance During Follow-up of Patients with Type 2 Diabetes”, Diabetes Care, 2001, vol. 24, No. 2, p. 362.
James B. Meigs, et al., “The Natural History of Progression from Normal Glucose Tolerance to Type 2 Diabetes in the Baltimore Longitudinal Study of Aging”, Diabetes, 2003, vol. 52, p. 1475.
David E Laaksonen, et al “Metabolic syndrome and Development of Diabetes Mellitus Application and Validation of Recently Suggested Definitions of the Metabolic syndrome in a Prospective Cohort Study”, American journal of Epidemiology, 2002, vol. 156, No. 11, p. 1070.
Earl S Ford, et al “Prevalence of the Metabolic Syndrome Among US Adults”, JAMA, 2002, vol. 287, No. 3, p. 356.
Matthews, et al. “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man”, Diabetologia, 1985, vol. 28, p. 412-419.
Galvin, et al “A Simple method for Quantitation of insulin Sensitivity and Insulin Release from an Intravenous Glucose Tolerance Test”, Diabetic Medicine, 1992, vol. 9, p. 921-928.
T. Forst, et al. “Fastening Intact Proinsulin is a Highly Specific indicator of Insulin Resistance in Type 2 Diabetes”, Diabetes, 2003, 52(Suppl. 1): A459.
Adelgoss Gebhard
Dugi Klaus
Duran Adil
Eickelmann Peter
Kraemer Gerd
Ajinomoto Co. Inc.
Lewis Patrick T
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
Crystalline form of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline form of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline form of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4180292